Richard Goldstein

Richard Goldstein discloses dealings in Canntab Therapeutics Limited to SEDI. The record holds 28 filings, for trades running from 11 April 2018 to 14 February 2022.

Both buying and selling appear: 18 purchases worth €393k, against 1 sale. No amount is published for 3 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 option exercises. So far in 2022, the count stands at 2 purchases and no sales.

In size, the median ticket on the buying side is €15k. The 16 purchases reviewed show no overlap with other insiders buying the same stock within a month.

Most recently, on 22 February 2022, the filings show a transaction in Canntab Therapeutics Limited. The last insider purchase was made public on 10 February 2022, 1,717 days ago. The median gap between a trade and its publication by SEDI is 2 days. The shorter that gap, the sooner other investors can see what insiders have done. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.